MHRA Compliance Regulations
BioPlex Peptides UK

The MHRA regulates medicines and medical devices in the UK and provides public services for reporting or checking suspicious online sellers of medicines and medical devices.

The MHRA has also published public guidance around GLP-1 medicines and has warned that prescription-only medicines should only be obtained from legitimate pharmacies with a valid prescription issued by a healthcare professional.

BioPlex Peptides will continue to monitor MHRA guidance, product classification issues, and wider regulatory developments affecting online research supply.

BioPlex Peptides is currently reviewing changes across the UK research peptide market following increased regulatory attention from the MHRA around the online sale of unauthorised medicinal products, prescription-only medicines, GLP-1 products, and other compounds that may fall under medicinal product classification.

The MHRA has made clear that selling fake, unsafe, unauthorised, or illegally supplied medicines online can have serious consequences and may be unlawful. The MHRA also operates reporting and checking services for suspicious online sellers and maintains a “Not Recommended” list for websites known for selling medicines illegally.

Recent MHRA activity has included enforcement action involving unlicensed weight loss medicines, including tirzepatide and retatrutide, as well as other peptide products. The MHRA has also stated that its Criminal Enforcement Unit works to disrupt illegal medicine supply chains, remove unsafe or unauthorised products, and bring prosecutions where appropriate.

As part of this changing regulatory environment, BioPlex Peptides has removed GLP-1 related products and other products identified for review. The MHRA Borderline Medicines team may review products individually to assess whether they fall within the definition of a medicinal product under the Human Medicines Regulations 2012. This means that the classification of a product is not decided only by how it is labelled, but also by its composition, presentation, intended purpose, claims, and how it is supplied.

BioPlex Peptides understands that some UK peptide websites are now being contacted and asked to remove certain products within a set timeframe, before further enforcement action is considered. This appears to be part of a wider compliance shift within the UK peptide market, with websites gradually removing products one by one as regulatory reviews continue.

Products currently under review or removed from public sale include, but may not be limited to:

Tirzepatide
Cagrilintide
Retatrutide
Semax
Selank
Gonadorelin
Hexarelin
Tesamorelin
Sermorelin
Melanotan 1
Melanotan 2
Melatonin
Kisspeptin
Mazdutide
Thymalin
Epitalon

BioPlex Peptides is treating this matter seriously and is reviewing product listings, product descriptions, website wording, customer-facing information, marketing content, and research-only disclaimers. Our aim is to remain aligned with UK regulatory expectations and to ensure that products are not presented in a way that could be interpreted as medicinal, therapeutic, diagnostic, cosmetic, dietary, weight-loss, or personal-use supply.

30th July 2026 Update: The Changing UK Peptide Market

During 2026, the UK peptide market has continued to evolve as the MHRA increases its focus on online sales, product presentation and the advertising of prescription-only medicines. Much of the industry's attention has centred on GLP-1 medicines and other products that already hold UK marketing authorisations or are regulated as prescription-only medicines. The MHRA has repeatedly emphasised that prescription-only medicines must not be promoted directly to the public and has continued enforcement activity in this area.

As regulatory expectations continue to develop, many suppliers across the UK have reviewed their websites, product catalogues and marketing content. In a number of cases, products that present a higher regulatory risk have been removed or revised while businesses assess their compliance obligations. This reflects a wider change across the sector rather than the actions of any single company.

At BioPlex Peptides, we continue to review our website, product information, educational content and customer communications to ensure they remain consistent with responsible research supply and current UK regulatory expectations. Where necessary, products, descriptions and supporting information may be updated as regulatory guidance evolves.

We believe transparency is an important part of responsible business practice. Rather than waiting for changes to become mandatory, we regularly review our content, monitor regulatory developments and make improvements where appropriate. Our objective is to provide clear product information while supporting legitimate laboratory research and maintaining high standards of quality, documentation and customer service.

What this means for customers

Ongoing review of product listings.

Regular updates to educational content.

Continued focus on research-only supply.

Clearer product information and documentation.

Monitoring MHRA guidance and regulatory developments.

Transparent communication whenever significant changes occur.

This page will be updated weekly as the situation develops and as further compliance reviews are completed.

For official MHRA information, visit the Medicines and Healthcare products Regulatory Agency on GOV.UK:
https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

You can also check or report suspicious online medicine sellers through the MHRA service here:
https://report-or-check-suspicious-activity.mhra.gov.uk/check

Read our full BioPlex Peptides MHRA Compliance Statement here:
UK Peptide Compliance and BioPlex Product Review – BioPlexPeptides.co.uk